A major hurdle in permanently eliminating HIV from the body is the persistence of viral reservoirs, including those of the brain. One potential strategy towards eradicating HIV reservoirs of the brain is to block efflux transporters, such as P-glycoprotein (P-gp), that contribute to the limited penetration of antiviral agents across the blood-brain barrier (BBB). Herein, we described a series of dimeric inhibitors of P-gp based on the nucleoside reverse transcriptase inhibitor and P-gp substrate, abacavir. Varying tether lengths were used to generate abacavir dimers to probe tether requirements for inhibitory potency. These dimeric agents were evaluated in two cell lines that express P-gp at varying levels: a P-gp overexpressing CD4
Introduction
Signicant progress has been made in developing therapeutic approaches for treatment of HIV using combination antiretroviral therapy (ART). Treatment with ART has successfully reduced viral plasma loads to undetectable levels in HIV infected individuals. Nevertheless, complete eradication of HIV by ART currently remains unattainable, as the virus persists in cellular and anatomical reservoirs, such as resting memory CD4 + cells, macrophages and the central nervous system (CNS).
1
Sanctuaries of HIV, such as those in the brain, are believed to occur, in part, due to limited penetration of ART into these sites.
2
The multidrug resistance transporter, P-glycoprotein (P-gp), is the most highly expressed member of the ATP-binding cassette (ABC) family of transporters at the blood brain barrier (BBB).
3 P-gp is localized to the apical membrane of the brain capillary endothelial cells where it actively transports a wide number of therapies, thereby limiting accumulation of these agents in the brain. 4 In vitro experiments have identied many substrates for P-gp, including a number of antiretrovirals, such as the protease inhibitors saquinavir, darunavir, amprenavir, nelnavir, ritonavir, and indinavir, and the reverse transcriptase inhibitor (RTI) prodrug abacavir. 2, 5 Additionally maraviroc, the HIV entry inhibitor that blocks the chemokine receptor CCR5, and the HIV integrase inhibitor raltegravir have been shown to be P-gp substrates. 6 The effect of P-gp on in vivo accumulation of antiretrovirals has also been investigated. For instance, experiments with P-gp-null mice have found a 20-fold increase in brain levels of the RTI abacavir versus wildtype mice. 7 The role of P-gp in limiting the penetration of ART across membranes such as those found in the endothelial cells of the BBB, points to the need for developing potent inhibitors of Pgp. In one example, the P-gp inhibitor ritonavir is oen coadministered to promote the brain penetration of antiviral therapies. However, ritonavir has a number of off-target interactions and extensive undesirable drug-drug interactions. Therefore, there is a great need for the development of new modulators of P-gp for co-administration with antiviral agents. Herein, we probe the role of tether length in a class of dimeric agents based on the antiviral agent abacavir. These agents effectively inhibit P-gp efflux, by targeting the membranebound drug binding region of P-gp, in a tether length-dependent fashion.
Results and discussion
Design and synthesis of library of abacavir dimers A number of biochemical studies have demonstrated that there are multiple substrate binding sites within the transporter region of P-gp.
8 Recent crystal structures of P-gp have also shown that the substrate binding region of P-gp is large enough to accommodate multiple substrate molecules, such as two cyclic peptides.
9 With these data in mind, we have developed a general strategy to convert therapeutic substrates of P-gp into P-gp inhibitors through dimerization. 10 In this way a monomeric P-gp substrate can be very quickly converted into an inhibitor through dimerization with the appropriate crosslinking agent. Using this strategy, we recently developed prodrug dimeric inhibitors of P-gp based on the RTI abacavir with invariant tether lengths.
10 However, we envisioned that by varying the length of the linker in the abacavir dimers we could optimize the inhibitory potency toward P-gp. With this in mind, we investigated ve homodimeric compounds consisting of abacavir linked to exible alkyl-based tethers via intervening ester bonds (Aba-C2-Aba-C10) (Scheme 1). The dimers were synthesized by treating abacavir with the corresponding PyBOPactivated bis-carboxylic acids in the presence of DIEA and DMAP (Scheme 1). The resulting abacavir dimers were puried to homogeneity by reversed phase HPLC.
Inhibition of P-gp by abacavir dimers is dependent on tether length

CD4
+ T-lymphocyte cells are a well-dened HIV reservoir that is established during early infection of HIV. 11 We employed the P-gp over-expressing CD4 + T-lymphocyte cell line, 12D7-MDR, as a model to evaluate the activity of the abacavir-based dimers. 12 Inhibition of P-gp efflux was determined by monitoring the cellular accumulation of the uorescent P-gp substrates calcein-AM and NBD-Aba in 12D7-MDR cells in the presence and absence of the dimers. In these assays, the P-gp over-expressing cells were incubated with the uorescent substrates and cellular uorescence was quantied by ow cytometry. The known P-gp inhibitor GF120918 was used as a positive control and DMSO (1%) was used as the negative control. An increase in cellular uorescence is indicative of inhibition of uorescent substrate efflux by P-gp from the cells.
All of the abacavir dimers were found to inhibit P-gp mediated efflux of both calcein-AM and NBD-Aba in a concentration dependent manner ( Table 1 ). The abacavir monomer, however, demonstrated no inhibition of efflux with either substrate up to a concentration of 500 mM. The efficacy of P-gp inhibition was dependent on the length of the tether; Aba-C2 was the least potent dimer in the library with an IC 50 value of 50 mM for inhibition of calcein-AM efflux. As the tether length of the abacavir dimers increased, a concomitant increase in potency was observed. For instance, Aba-C7 to Aba-C10 were found to be 20-to 35-fold more potent than the C2-analog with calcein-AM in 12D7-MDR cells.
Given that our goal is to inhibit P-gp at the BBB as a means to increase brain penetration of ART, we also utilized an immortalized human brain capillary endothelial cell line as an in vitro model of the BBB (hCMEC/D3 cells). Importantly, this cell line expresses endogenous levels of P-gp 13 and also retains many of the key characteristics of primary brain endothelial cells without the need to co-culture with glial cells.
14 We performed substrate accumulation assays with NBD-Aba in the presence and absence of the abacavir dimer series. As above, DMSO (1%) alone was used as the negative control and GF10918 (1 mM) was the positive control. The abacavir dimers all inhibited P-gp efflux of NBD-Aba in the human brain capillary cells to varying degrees (Table 1 ). The most potent dimer, Aba-C10, was greater than 500-fold more potent than monomeric abacavir, with an IC 50 of 1.1 mM. These data indicate that abacavir dimers were effective inhibitors of P-gp expressed at endogenous levels in capillary endothelial cells of the BBB.
A major concern for long-term administration of ART is the potential for some agents, like the protease inhibitors atazanavir and ritonavir, to induce the expression of efflux transporters such as P-gp. This up-regulation of P-gp expression can serve to further limit the penetration P-gp sensitive ART into cells. 15 To test how well the abacavir dimers function in a P-gp over-expressing environment, we used the human breast carcinoma cell line MCF-7/DX1 that expresses high levels of P-gp (10-fold greater levels than 12D7-MDR cells 16 ). Substrate accumulation assays were performed to determine the efficacy of Aba-C8 with four different P-gp substrates, BODIPY-prazosin, doxorubicin, [ 3 H]-daunomycin and NBD-Aba; Aba-C8 was used due to more favorable solubility in aqueous buffer as compared to Aba-C10. Cellular accumulation of the uorescent substrates in the presence of increasing concentrations of the dimers was quantied by ow cytometry, and the accumulation of [ 3 H]-daunomycin was quantied by scintillation counting. In the absence of Aba-C8, very low levels of cellular uorescence or radioactivity was observed with the four different P-gp substrates as they are effectively effluxed from the cells by P-gp ( Fig. 1A-D) . As the concentration of Aba-C8 was increased, we observed an increased level of the uorescent or radioactive substrates within cells due to inhibition of P-gp. Aba-C8 was found to effectively inhibit efflux for each of the substrates (Fig. 1 ), whereas monomeric abacavir had no effect on transport up to a concentration of 100 mM (data not shown). These data demonstrate that one of the more potent abacavir dimers of this series was capable of inhibiting the efflux of therapeutics in cells that express high levels of P-gp. The potency of Aba-C8 in MCF-7/DX1 cells, however, was decreased about 3-to 6-fold using NBD-Aba as a substrate in hCMEC/D3 and 12D7-MDR, respectively.
Abacavir dimers inhibit P-gp by competing for substrate binding sites
We designed the abacavir dimers to interact with substrate binding sites located within the transmembrane region of P-gp. Therefore, the dimers should compete with P-gp substrates for these binding sites. (Fig. 2B) . These data support the hypothesis that Aba-C8 inhibits P-gp by interacting with the substrate binding sites.
Experimental procedures
General synthesis of abacavir dimers
To a solution of bis-carboxylic acid (0.06 mmol) in dry dimethylformamide (DMF) (2 mL) at À20 C was added benzotriazol-1-yl-oxytripyrrolidinophosphonium hexauorophosphate (PyBOP) (0.18 mmol), 4-dimethylaminopyridine (DMAP) (0.03 mmol), and diisopropylamine DIEA (0.6 mmol). Aer 20 min at À20 C, abacavir (0.18 mmol) was added. The mixture was stirred for 8 hours at À20 C, allowed to warm to room temperature and stirred for an additional 8 hours. The solvent was removed in vacuo, the resulting material was dissolved in dimethylsulfoxide (DMSO) and puried by reverse phase HPLC using a C5 semi-preparative column (Phenomenex, USA) with an eluent consisting of solvent A (methanol and 0.1% triuoroacetic acid (TFA)) and solvent B (water and 0.1% TFA) with a 60 min gradient of 20-95% solvent A, a ow rate of 20.0 mL min À1 and UV detection at 214 nm and 285 nm. Fractions consisting of the desired dimers were collected and lyophilized to obtain Aba-C2 (22% yield), Aba-C5 (26% yield), Aba-C7 (68% yield), Aba-C8 (70% yield) and Aba-C10 (58% yield). . Purity ($96%) was characterized by analytical HPLC, retention time 21.9 min using a C5 analytical column (Phenomenex, USA) with an eluent consisting of solvent A (methanol and 0.1% triuoroacetic acid (TFA)) and solvent B (water and 0.1% TFA) with a 30 min gradient of 20-95% solvent A, and a ow rate of 1.2 mL min À1 . .
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Cell culture
12D7-MDR cells (CD4 + human T-lymphocytic cell line)
expressing P-gp were cultured in RPMI 1640 supplemented with 10% Fetal Bovine Serum (Cambrex Bioscience, WalkersVille, Inc.), 5 mM L-glutamine, 50 units mL À1 penicillin and 50 mg mL À1 streptomycin (Cellgro Mediatech). Cells were incubated at 37 C with 5% carbon dioxide. Sf9 cells were cultured at 27 C in Sf-900 II SFM medium supplemented with 0.5Â antibioticantimycotic (Invitrogen). The hCMEC/D3 cell line was cultured as described previously with slight modications. 15 The cells were maintained in endothelial growth medium-2 (EGM-2) from Lonza (Walkersville, MD), supplemented with 5% fetal bovine serum, 1% penicillin-streptomycin, 0.5% human basic broblast growth factor (hbFGF), 0.05% hydrocortisone, 0.5% ascorbic acid, 1% HEPES and 1% lipid concentrate at 37 C and 5% CO 2 . Cells were passaged into collagenated culture asks every 3-4 days at approximately 85-95% conuence. MCF-7/DX1 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine (Mediatech, Herndon, VA), 50 units mL À1 penicillin, 50 mg mL À1 streptomycin (Mediatech), and 1 mM doxorubicin.
Expression of P-gp in insect cells
Sf9 cells in 150 cm 2 asks (1.86 Â 10 7 cells per ask) were infected with BV-MDR1 that expresses human P-gp as previously described. 18 Aer 2 hours of incubation at 27 C, the cells were treated with 15 mL of culture medium and incubated at 27 C for another 72 hours.
Preparation of crude insect cell membranes
BV-MDR1 infected Sf9 cells were collected and crude membrane extracts were prepared as described previously. 18 P-gp expression was veried by immunoblot analysis with C219 primary antibody (1 : 8000) and HRP-conjugated anti-mouse secondary antibody (1 : 8000). Probe bands were visualized using enhanced chemiluminescence (ECL) (Pierce).
Flow cytometry assays
Flow cytometry assays were performed as previously described, with a few modications. 19 For assays with 12D7-MDR cells or hCMEC/D3 cells, an aliquot of the substrate uorophore (calcein-AM or NBD-Aba) dissolved in DMSO was added to prewarmed basal medium eagle (BME) media to give a nal concentration of 0.25 mM for calcein-AM or 5 mM for NBD-Aba. The uorophore treated BME media (1 mL) was incubated with 125 000 cells (in suspension) in the presence of increasing concentrations of the dimeric abacavir agents at 37 C for 30 min, keeping the DMSO concentration at a constant 1%. 1 mM GF120918 was used as a positive control. Cells were collected by centrifugation and re-suspended in ice-cold phosphate buffered saline (PBS, pH 7.4). The cells were analyzed for uorescent substrate accumulation using a FACSCalibur ow cytometer (BD Biosciences, San Jose, CA) equipped with a 488 nm argon laser and a 530 nm band pass lter (FL1). Ten thousand cells were counted for each data point and the mean uorescence was used to determine the IC 50 values using Sigma plot. For assays with MCF-7/DX1 cells, 125 000 cells suspended in BME media (1 mL) that were previously treated with either doxorubicin (nal concentration of 3 mM), BODIPY-prazosin (nal concentration of 0.5 mM) or NBD-Aba (nal concentration 5 mM) were incubated alone or with increasing concentrations of abacavir dimers for 30 min at 37 C, keeping the concentration of DMSO at a constant 1%. 1 mM GF120918 was used as a positive control. For doxorubicin, cells were harvested by centrifugation followed by re-suspension in pre-warmed BME media with 1 mM GF120918 or varying concentrations of abacavir dimers. The cells were incubated for an additional 30 min at 37 C. These cells, and those treated with BODIPY-prazosin and NBD-Aba were harvested by centrifugation, the media was removed and the cells were resuspended in 350 mL of ice cold PBS, pH 7.4. The cells were analyzed using a FACSCalibur ow cytometer (BD Biosciences, San Jose, CA) equipped with a 488 nm argon laser and a 530 band pass lter (FL1) for NBD-Aba and BODIPY-prazosin, and a 585/42 band pass lter (FL2) for doxorubicin. IC 50 values were obtained as described above.
Radioactive substrate accumulation assays
Radioactive assays were performed as previously described with minor modications. 19 Six-well plates were seeded with 500 000 MCF-7/DX1 cells per well in RPMI 1640 media a day before the assay. The next day, the media in the wells was removed and the cells were washed twice with ice cold PBS. The cells were incubated with BME media supplemented with 5% calf serum and 0.25 mCi mL À1 [ 3 H]-daunomycin alone or with varying concentrations of abacavir dimers or GF120918 (1 mM) for 40 min at 37 C. The media was removed and the cells were washed twice with 1 mL ice cold PBS. Pre-warmed trypsin-EDTA (1 mL) was added and the cells were incubated for 1 h at 37 C. The contents of the wells were transferred into scintillation vials containing 18 mL of EcoLite(+) scintillation uid (MR Research Products, Irvine, CA). Each well was washed twice with 500 mL ice cold PBS and the contents added to the scintillation vials. Each vial was counted using a 1600 CA tri-CARB liquid scintillation analyzer (Packard Instrument Company, Downers Grove, IL). The data obtained was normalized to counts per 10 000 cells. The IC 50 values were acquired from the concentrationdependent data that was tted using GraphPad Prism 4.
IAAP photoaffinity labeling
Photoaffinity labeling was performed as described previously with some modications. 19 Crude Sf9 membranes expressing P-gp (25 mg) were incubated for 10 min at room temperature in the dark in assay buffer (Tris-HCl (50 mM), pH 7.5, 1% aprotinin, 1 mM DTT, and 2 mM 4-(2-aminoethyl) benzenesulfonyl uoride hydrochloride) with either 2.5% DMSO or GF120918 (a nal concentration of 10 mM) or increasing concentrations of the abacavir dimers and [ 125 I]-IAAP (1 mL, specic activity of $2200 Ci mmol À1 ). The samples were illuminated with UV light (365 nm) for 20 min on ice. Samples were separated by SDS-PAGE using a 7.5% tris gel. The gel was xed and allowed to dry overnight. Following exposure to X-ray lm at À80 C, the gel band corresponding to P-gp was analyzed using 
Conclusion
A signicant obstacle to delivering ART at therapeutic levels to viral reservoirs, such as those in the brain, is the efflux activity of P-gp. With the ultimate goal of increasing the brain penetration of ART, we developed a series of dimeric inhibitors of P-gp based on the P-gp substrate and RTI abacavir. These dimers were designed with varying tether lengths, and were found to inhibit P-gp mediated efflux of substrates such as calcein-AM and NBD-Aba in several P-gp expressing mammalian cell lines. Importantly, the dimers inhibited P-gp both in human brain capillary cells that express endogenous levels of the transporter and in CD4 + T-cells that overexpress P-gp. In both cell lines, inhibitory potency increased with tether length, with Aba-C7 to Aba-C10, being the most potent agents tested. Furthermore, the representative dimeric agent Aba-C8 was shown to inhibit P-gp efflux of four therapeutic agents in a cell line that highly over-expresses P-gp, MCF-7/DX1 cells. Aba-C8 was also shown to inhibit P-gp by competing for substrate binding sites. Ultimately, agents such as the designed abacavir dimers could be co-administered with monomeric abacavir to improve brain penetration in antiviral treatment.
